Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxytriptolide in Active Rheumatoid Arthritis
NCT02202395Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jun 2014
- Primary completion
- Apr 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydroxytriptolide in rheumatoid arthritis (RA) (4 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Jun 2014; status: completed.
02
Drugs
hydroxytriptolide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02202395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202395.